Caribou Biosciences, Inc. (CRBU)

1,6400 -0,0400 (-2,38%) Alla chiusura: 04:00PM EDT

Caribou Biosciences, Inc.

2929 7th Street
Suite 105
Berkeley, CA 94710
United States
510 982 6030
https://cariboubio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 158

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Rachel E. Haurwitz Ph.D.	Co-Founder, CEO, President & Director	979,08k	N/D	1986
Dr. Steven B. Kanner Ph.D.	Chief Scientific Officer	669,31k	N/D	1960
Ms. Barbara G. McClung Esq., J.D.	Chief Legal Officer & Corporate Secretary	669,31k	N/D	1955
Mr. Jason V. O'Byrne M.B.A.	CFO & Principal Accounting Officer	586,36k	N/D	1969
Mr. Daniel Poon	Vice President of Operations & Information Technology	N/D	N/D	N/D
Mr. Timothy P. Kelly M.B.A.	Chief Technology Officer	N/D	N/D	1969
Ms. Amy Figueroa C.F.A.	Vice President of Investor Relations & Corporate Communications	N/D	N/D	N/D
Ms. Reigin Zawadzki	Chief People Officer	N/D	N/D	N/D
Ms. Ruhi A. Khan M.B.A.	Chief Business Officer	573,9k	N/D	1975
Mr. Ryan Fischesser	Vice President of Finance & Controller	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Governance aziendale

L'ISS Governance QualityScore di Caribou Biosciences, Inc. al 1 giugno 2024 è 7. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 5; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.